OQROGet OQRO Pro
Politician trade (House)

Eli Lilly (LLY)Rep. Michael Rulli (OH06) disclosed a sale $1K–$15K

Rep. Michael Rulli (OH06) disclosed a sale of Eli Lilly in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
248 days
Disclosure lag
Traded
Dec 2, 2025
Disclosed
Aug 7, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 23, 2025CongressDisclosed sale of LLY — reported range $1,001 - $15,000
  2. Oct 2, 2025Insider · 1 personInsiders: 9 sales (~$92.5M)
  3. Oct 3, 2025Insider · 1 personInsiders: 25 sales (~$161.2M)
  4. Oct 6, 2025Insider · 1 personInsiders: 8 sales (~$137.0M)
  5. Oct 7, 2025Insider10% owner sold ~$22.7M of LLY shares in the open market
  6. Oct 8, 2025Insider · 1 personInsiders: 8 sales (~$86.2M)
  7. Oct 9, 2025Insider · 1 personInsiders: 8 sales (~$9.0M)
  8. Oct 10, 2025Insider · 1 personInsiders: 2 sales (~$3.2M)
  9. Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
  10. Oct 30, 20255% stakeThe Vanguard Group reported a passive stake (13G) of 8.6%
  11. Oct 30, 20255% stakeLILLY ENDOWMENT, INC. reported a passive stake (13G) of 10.1%
  12. Oct 31, 2025Insider · 1 personInsiders: 8 sales (~$260.2M)
  13. Nov 3, 2025Insider · 1 personInsiders: 10 sales (~$118.2M)
  14. Nov 18, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 18, 2025, the Board of Directors (the “Board”) of Eli Lilly and Company (the “Company”) elected Carolyn R. Bertozzi, Ph.D as a new member of the Board, effective December 8, 2025.”
  15. Nov 20, 2025FDAFDA drug approval: Retevmo
  16. Nov 20, 2025FDAFDA drug approval: Retevmo

What came next

  1. Dec 19, 2025FDAFDA drug approval: Mounjaro
  2. Jan 23, 20265% stakeLILLY ENDOWMENT, INC. reported a passive stake (13G) of 9.8%
  3. Feb 4, 2026Company filing · Form 8-K · ResultsReported its results
  4. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  5. Apr 1, 2026FDAFDA drug approval: Foundayo
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Eli Lilly

For Eli Lilly, OQRO holds 7 insider filings (SEC Form 4 or Form 144), 5 Congress trade reports, 189 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LLY page.

Other recent filings by Rep. Michael Rulli (OH06)

The full history of Rep. Michael Rulli (OH06) is on the profile page.

How this filing works

Other disclosures at Eli Lilly

Everything OQRO holds on this company is on its LLY page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data